NYSE : AZN
AstraZeneca PLC — Key statistics
Healthcare · Drug Manufacturers - General · United Kingdom
Last price 174.4 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 270.72B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 290.07B |
| Enterprise Value | 316.56B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Aug 7, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 1.55B |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | -0.02% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 74.04% |
| Float | 1.54B |
Ratios
| Measure | Value |
|---|
| PE Ratio | 26.17 |
| Forward PE | 16.94 |
| PS Ratio | 4.65 |
| Forward PS | 4.40 |
| PB Ratio | 5.60 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 28.41 |
| P/OCF Ratio | 21.92 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 28.70 |
| EV / Sales | 5.07 |
| EV / EBITDA | 14.88 |
| EV / EBIT | 19.67 |
| EV / FCF | 31.00 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.01 |
| Quick Ratio | 0.79 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 1.58 |
| Debt / FCF | 3.36 |
| Interest Coverage | 11.05 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 22.57% |
| Return on Assets (ROA) | 8.58% |
| Return on Invested Capital (ROIC) | 17.15% |
| Return on Capital Employed (ROCE) | 18.16% |
| Weighted Average Cost of Capital (WACC) | 5.22% |
| Revenue Per Employee | $655,983 |
| Profits Per Employee | $115,983 |
| Employee Count | 95,100 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.69 |
Taxes
| Measure | Value |
|---|
| Income Tax | 2.27B |
| Effective Tax Rate | 17.04% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.21 |
| 52-Week Price Change | +14.04% |
| 50-Day Moving Average | 164.48 |
| 200-Day Moving Average | 180.04 |
| Relative Strength Index (RSI) | 75.14 |
| Average Volume (20 Days) | 3,012,134 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.28M |
| Short Previous Month | 2.09M |
| Short % of Shares Out | 0.21% |
| Short % of Float | 0.21% |
| Short Ratio (days to cover) | 1.14 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 62.38B |
| Gross Profit | 51.02B |
| Operating Income | 16.10B |
| Pretax Income | 13.30B |
| Net Income | 11.03B |
| EBITDA | 21.28B |
| EBIT | 16.10B |
| Earnings Per Share (EPS) | $7.13 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 8.17B |
| Total Debt | 34.33B |
| Net Cash | -26.16B |
| Net Cash Per Share | -$16.87 |
| Equity (Book Value) | 51.81B |
| Book Value Per Share | 33.35 |
| Working Capital | 181.00M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 13.23B |
| Capital Expenditures | -3.02B |
| Depreciation & Amortization | 5.18B |
| Net Borrowing | 564.00M |
| Free Cash Flow | 10.21B |
| FCF Per Share | $6.58 |
Margins
| Measure | Value |
|---|
| Gross Margin | 81.78% |
| Operating Margin | 25.80% |
| Pretax Margin | 21.32% |
| Profit Margin | 17.68% |
| EBITDA Margin | 34.11% |
| EBIT Margin | 25.80% |
| FCF Margin | 16.37% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | $3.23 |
| Dividend Yield | 1.73% |
| Dividend Growth (YoY) | 3.19% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 45.34% |
| FCF Payout Ratio | 49.07% |
| Buyback Yield | 0.02% |
| Shareholder Yield | 1.75% |
| Earnings Yield | 3.82% |
| FCF Yield | 3.52% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $206.66 |
| Price Target Difference | 10.72% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 6.74% |
| EPS Growth Forecast (3Y) | 11.27% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.6 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |